EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS‐CoV‐2 infection

Zeno Pasquini iD, Alice Toschi, Beatrice Casadei, Cinzia Pellegrini, Alessandra D'Abramo, Serena Vita, Alessia Beccacece, Linda Bussini, Maria Clara Chionsini, Nicola Dentale, Alessia Cantiani, Tiziana Lazzarotto und 5 weitere

Hematological Oncology · 2023-12 · 41 (5) · 904-911

DOI: 10.1002/hon.3206 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hematological Oncology, online erschienen am 15.07.2023. Verfasst von Zeno Pasquini und 16 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy. Hauptthemen laut MEDLINE: Ritonavir, COVID-19. Die Arbeit wurde bisher 44-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite global vaccination efforts, immunocompromized patients remain at high risk for COVID‐19‐associated morbidity. In particular, patients with impaired humoral immunity have shown a high risk of persistent infection. We report a case series of adult patients with B cell malignancies and/or undergoing B cell targeting therapies with persisting SARS‐CoV‐2 infection and treated with a combination antiviral therapy of remdesivir and nirmatrelvir/ritonavir, in three Italian tertiary academic hospitals. A total of 14 patients with impaired adaptive humoral immunity and prolonged SARS‐CoV‐2 infection were treated with the dual antiviral therapy. The median age was 60 (IQR 56–68) years, and 11 were male. Twelve patients had B cell lymphoma, one patient had chronic lymphocytic leukemia and one patient had multiple sclerosis. Thirteen out of 14 patients had received prior B cell‐targeting therapies, consisting of anti‐CD20 monoclonal antibodies in 11 patients, and chimeric antigen receptor T therapy in 2 patients. The median time between diagnosis and therapy start was 42.0 (IQR 35–46) days. Seven patients had mild, 6 moderate and one severe disease. Nine patients had signs of interstitial pneumonitis on chest computed tomography scans before treatment. The median duration of nirmatrelvir/ritonavir and remdesivir combination therapy was 10 days. All patients showed resolution of COVID‐19‐related symptoms after a median of 6 (IQR 4–11) days and viral clearance after 9 (IQR 5–11) days. Combination therapy with remdesivir and nirmatrelvir/ritonavir is a promising treatment option for persistent COVID‐19 in immunocompromized patients with humoral immunity impairment, worthy of prospective comparative trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RitonavirCOVID-19AdultHumansMaleMiddle AgedFemaleImmunity, HumoralProspective StudiesCOVID-19 Drug TreatmentSARS-CoV-2Antiviral AgentsLactamsLeucineNitrilesProlineAdenosine MonophosphateAlanine

Stichwörter der Autor:innen

B cell malignanciesB cell targeting therapiesCOVID-19persistent SARS-CoV-2 infectionviral infections in the hematological patient

Substanzen

RitonavirAntiviral AgentsnirmatrelvirLactamsLeucineNitrilesProlineremdesivirAdenosine MonophosphateAlanine

Autor:innen und Institutionen

  • Infectious Diseases Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Institute of Hematology "L. e A. Seràgnoli", IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
  • National Institute for Infectious Diseases "Lazzaro Spallanzani", IRCCS, Rome, Italy.
  • Infectious Disease Unit, IRCCS Humanitas Research Hospital, Milan, Italy.
  • Department of Biomedical Sciences, Humanitas University, Milan, Italy.

ORCID-Profile: Zeno Pasquini, Pierluigi Zinzani

Zitieren

APA

Pasquini, Z., Toschi, A., Casadei, B., Pellegrini, C., D'Abramo, A., Vita, S., Beccacece, A., Bussini, L., Chionsini, M. C., Dentale, N., Cantiani, A., Lazzarotto, T., Bartoletti, M., Nicastri, E., Zinzani, P., Giannella, M., & Viale, P. (2023). Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS‐CoV‐2 infection. Hematological Oncology, 41(5), 904-911. https://doi.org/10.1002/hon.3206

Vancouver

Pasquini Z, Toschi A, Casadei B, Pellegrini C, D'Abramo A, Vita S, et al. Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS‐CoV‐2 infection. Hematological Oncology. 2023;41(5):904-911. doi:10.1002/hon.3206

BibTeX
@article{Pasquini2023,
  author = {Pasquini, Zeno and Toschi, Alice and Casadei, Beatrice and Pellegrini, Cinzia and D'Abramo, Alessandra and Vita, Serena and Beccacece, Alessia and Bussini, Linda and Chionsini, Maria Clara and Dentale, Nicola and Cantiani, Alessia and Lazzarotto, Tiziana and Bartoletti, Michele and Nicastri, Emanuele and Zinzani, Pierluigi and Giannella, Maddalena and Viale, Pierluigi},
  title = {Dual combined antiviral treatment with remdesivir and nirmatrelvir/ritonavir in patients with impaired humoral immunity and persistent SARS‐CoV‐2 infection},
  journal = {Hematological Oncology},
  year = {2023},
  volume = {41},
  number = {5},
  pages = {904--911},
  doi = {10.1002/hon.3206}
}
Kostenlos starten →